Vivek Subbiah/LinkedIn
Jun 4, 2025, 06:15
Vivek Subbiah: Tumor-agnostic Precision Oncology – Finding vs Threading The Needle
Vivek Subbiah, Chief of Early-Phase Drug Development at the Sarah Cannon Research Institute, shared on X:
“Tumor-agnostic precision oncology: finding vs threading the needle. This figure illustrates the dual challenges in tumor-agnostic precision oncology.
On one hand, we have achieved significant advances in identifying actionable alterations across various cancer types, akin to “finding the needle” in a haystack.
On the other hand, the “threading the needle” analogy highlights the current challenges in aligning these identified alterations with optimal therapeutic strategies, ensuring that patients receive the most effective treatments tailored to their unique genetic profiles.”
Title: Tissue-agnostic cancer therapies: promise, reality, and the path forward
Author: Vivek Subbiah
Read OncoDaily’s Special Articles about ASCO 2025:
Highlights from ASCO 2025 Day 1
Highlights from ASCO 2025 Day 2
Highlights from ASCO 2025 Day 3
Highlights from ASCO 2025 Day 4
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Jun 4, 2025, 17:02
Jun 4, 2025, 16:33
Jun 4, 2025, 16:33
Jun 4, 2025, 15:56
Jun 4, 2025, 14:21
Jun 4, 2025, 13:42